Esperion Therapeutics Inc
NASDAQ:ESPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Esperion Therapeutics Inc
NASDAQ:ESPR
|
US |
|
Harboes Bryggeri A/S
CSE:HARB B
|
DK |
|
Electrolux AB
STO:ELUX B
|
SE |
|
scPharmaceuticals Inc
NASDAQ:SCPH
|
US |
|
ValueCommerce Co Ltd
TSE:2491
|
JP |
|
GXO Logistics Inc
NYSE:GXO
|
US |
|
G
|
Gold&S Co Ltd
KOSDAQ:035290
|
KR |
|
True North Copper Ltd
ASX:TNC
|
AU |
|
S
|
Schneider Electric SE
F:SND
|
FR |
|
Maruwa Co Ltd
LSE:MAW
|
JP |
|
Ohsho Food Service Corp
TSE:9936
|
JP |
|
I
|
Ichitan Group PCL
SET:ICHI
|
TH |
|
QNB Finansbank AS
IST:QNBFB.E
|
TR |
|
Zhejiang Meorient Commerce & Exhibition Inc
SZSE:300795
|
CN |
|
Permascand Top Holding AB
F:69U
|
SE |
|
B
|
Belon OAO
MOEX:BLNG
|
RU |
|
Nexus AG
XETRA:NXU
|
DE |
|
I
|
ICSGlobal Ltd
ASX:ICS
|
AU |
|
N
|
NeoVolta Inc
NASDAQ:NEOV
|
US |
|
L
|
Lenskart Solutions Ltd
NSE:LENSKART
|
IN |
|
A
|
Advanced Oxygen Technologies Inc
OTC:AOXY
|
US |
|
F
|
Fuji Seal International Inc
TSE:7864
|
JP |
Esperion Therapeutics Inc
Esperion Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Ann Arbor, Michigan and currently employs 218 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The firm's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Esperion Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Ann Arbor, Michigan and currently employs 218 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The firm's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Acquisition: Esperion announced a planned acquisition of Corstasis to gain global rights to Enbumyst (intranasal loop diuretic); transaction expected to close in Q2 2026 and is positioned as transformational for growth.
Revenue: Q4 2025 total revenue was $168.4 million, up 144% year-over-year, driven largely by a $90 million one-time payment from Otsuka and stronger partner royalties/sales.
U.S. Franchise: U.S. net product revenue was $43.7 million in Q4, up ~38% YoY; retail prescription equivalents up 34% and number of unique prescribers up nearly 25%.
Guidelines / Market Tailwind: Management expects imminent U.S. dyslipidemia guideline inclusion (likely released just before ACC mid-March) and views this as a clear tailwind for bempedoic acid placement and awareness.
International traction: Daiichi Sankyo has treated >700,000 patients and Q4 Europe royalties grew strongly (Daiichi Europe Q4 royalty revenue +51% YoY); Otsuka launched successfully in Japan with favorable NHI pricing.
Pipeline & combos: Esperion is advancing triple combination oral programs (bempedoic acid + ezetimibe + statin) and expects to complete clinical/regulatory requirements to commercialize in 2027.
Balance sheet & guidance: Cash and equivalents $167.9 million at year-end 2025; company paid off $55 million of debt (convertible note stub); 2026 operating expense guidance $225–$255 million (includes $15 million stock comp).
Enbumyst opportunity: Enbumyst addresses outpatient heart failure diuresis (U.S. outpatient market >$4 billion cited); product available now and expected to allow cross-selling into current cardiology base.
